Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Jul 2016

Zhou Jing-Dong, Zhang Ting-Juan, Wang Yu-Xin, Yang Dong-Qin, Yang Lei, Ma Ji-Chun, Wen Xiang-Mei, Yang Jing, Lin Jiang, Qian Jun

Abstract excerpt

Hypermethylation of distal-less homeobox 4 (DLX4) has been increasingly identified in several cancers. Our study was aimed to determine the role of DLX4 methylation in regulating DLX4 expression and further analyze its clinical significance in de novo acute myeloid leukemia (AML) patients. DLX4 methylation level was detected by real-time quantitative methylation-specific PCR and bisulfite sequencing PCR....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methylation

Share to Homeodomain Proteins

Share to Leukemia, Myeloid, Acute

Share to Prognosis

Share to Remission Induction

Share to RNA, Messenger

Source

Identifiers

PMID: 26753961
DOI: 10.1007/s13277-015-4364-4

Genes

DLX4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia.PMID 26753961Read ↗

BP1 overexpression is associated with adverse prognosis in de novo acute myeloid leukemia.Semantic proximity Read ↗

Identification and validation of prognosis‐related DLX5 methylation as an epigenetic driver in myeloid neoplasmsSemantic proximity Read ↗

Hypermethylation of DLX4 predicts poor clinical outcome in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemiaSemantic proximity Read ↗

Higher HOPX expression is associated with distinct clinical and biological features and predicts poor prognosis in de novo acute myeloid leukemiaSemantic proximity Read ↗

ALOX5AP is a new prognostic indicator in acute myeloid leukemiaSemantic proximity Read ↗

Aberrant DNA methylation of key genes and Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia.Semantic proximity Read ↗

CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.Semantic proximity Read ↗

CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemiaSemantic proximity Read ↗

A regulatory element in the 3'-untranslated region of CEBPA is associated with myeloid/NK/T-cell leukemia.Semantic proximity Read ↗

Identification and validation of HOXB3 hypomethylation as a novel prognostically epigenetic biomarker in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.